Bladder Cancer

Urinary BladderA Randomized Phase II, Double-blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-risk Muscle-invasive Urothelial Carcinoma
Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Other Urinary, Pancreas, Phase I, Urinary BladderA Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors
Colon, Liver, Lung, Other Skin, Other Urinary, Phase I, Rectum, Urinary BladderA Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Urinary BladderA Phase II Study of Consolidative Local Therapy in Patients With Locally Advanced or Oligo-metastatic Urothelial Carcinoma (la/mUC) Following Treatment Response to Systemic Therapy With or Without Metastasis-directed RadiotherapyPrincipal Investigator: Fed Ghali
Prostate, Urinary BladderAn Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)